Daniel SW Tan
Cited by
Cited by
Ceritinib in ALK-rearranged non–small-cell lung cancer
AT Shaw, DW Kim, R Mehra, DSW Tan, E Felip, LQM Chow, DR Camidge, ...
N Engl j med 370, 1189-1197, 2014
First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study
JC Soria, DSW Tan, R Chiari, YL Wu, L Paz-Ares, J Wolf, SL Geater, ...
The Lancet 389 (10072), 917-929, 2017
Isolation and retrieval of circulating tumor cells using centrifugal forces
HW Hou, ME Warkiani, BL Khoo, ZR Li, RA Soo, DSW Tan, WT Lim, J Han, ...
Scientific reports 3 (1), 1-8, 2013
A common BIM deletion polymorphism mediates intrinsic resistance and inferior responses to tyrosine kinase inhibitors in cancer
KP Ng, AM Hillmer, CTH Chuah, WC Juan, TK Ko, ASM Teo, ...
Nature medicine 18 (4), 521, 2012
Slanted spiral microfluidics for the ultra-fast, label-free isolation of circulating tumor cells
ME Warkiani, G Guan, KB Luan, WC Lee, AAS Bhagat, PK Chaudhuri, ...
Lab on a Chip 14 (1), 128-137, 2014
Bystander CD8+ T cells are abundant and phenotypically distinct in human tumour infiltrates
Y Simoni, E Becht, M Fehlings, CY Loh, SL Koo, KWW Teng, JPS Yeong, ...
Nature 557 (7706), 575-579, 2018
Activity and safety of ceritinib in patients with ALK-rearranged non-small-cell lung cancer (ASCEND-1): updated results from the multicentre, open-label, phase 1 trial
DW Kim, R Mehra, DSW Tan, E Felip, LQM Chow, DR Camidge, ...
The lancet oncology 17 (4), 452-463, 2016
Liquid biopsy for advanced non-small cell lung cancer (NSCLC): a statement paper from the IASLC
C Rolfo, PC Mack, GV Scagliotti, P Baas, F Barlesi, TG Bivona, RS Herbst, ...
Journal of Thoracic Oncology 13 (9), 1248-1268, 2018
Human innate lymphoid cell subsets possess tissue-type based heterogeneity in phenotype and frequency
Y Simoni, M Fehlings, HN KlÝverpris, N McGovern, SL Koo, CY Loh, ...
Immunity 46 (1), 148-161, 2017
Biomarker-driven early clinical trials in oncology: a paradigm shift in drug development
DSW Tan, GV Thomas, MD Garrett, U Banerji, JS De Bono, SB Kaye, ...
The Cancer Journal 15 (5), 406-420, 2009
Concurrent chemo-radiation with or without induction gemcitabine, carboplatin, and paclitaxel: a randomized, phase 2/3 trial in locally advanced nasopharyngeal carcinoma
T Tan, WT Lim, KW Fong, SL Cheah, YL Soong, MK Ang, QS Ng, D Tan, ...
International Journal of Radiation Oncology* Biology* Physics 91 (5), 952-960, 2015
Progression-free and overall survival in ALK-positive NSCLC patients treated with sequential crizotinib and ceritinib
JF Gainor, DSW Tan, T De Pas, BJ Solomon, A Ahmad, C Lazzari, ...
Clinical cancer research 21 (12), 2745-2752, 2015
The international association for the study of lung cancer consensus statement on optimizing management of EGFR Mutation–Positive Non–Small cell lung cancer: status in 2016
DSW Tan, SS Yom, MS Tsao, HI Pass, K Kelly, N Peled, RC Yung, ...
Journal of Thoracic Oncology 11 (7), 946-963, 2016
An ultra-high-throughput spiral microfluidic biochip for the enrichment of circulating tumor cells
ME Warkiani, BL Khoo, DSW Tan, AAS Bhagat, WT Lim, YS Yap, SC Lee, ...
Analyst 139 (13), 3245-3255, 2014
Targeting RET-driven cancers: lessons from evolving preclinical and clinical landscapes
A Drilon, ZI Hu, GGY Lai, DSW Tan
Nature Reviews Clinical Oncology 15 (3), 151, 2018
Novel therapeutic targets on the horizon for lung cancer
WL Tan, A Jain, A Takano, EW Newell, NG Iyer, WT Lim, EH Tan, W Zhai, ...
The Lancet Oncology 17 (8), e347-e362, 2016
Randomized trial comparing surgery and adjuvant radiotherapy versus concurrent chemoradiotherapy in patients with advanced, nonmetastatic squamous cell carcinoma of the head†…
NG Iyer, DSW Tan, VKM Tan, W Wang, J Hwang, NC Tan, R Sivanandan, ...
Cancer 121 (10), 1599-1607, 2015
Cancer genomics: diversity and disparity across ethnicity and geography
DS Tan, TS Mok, TR Rebbeck
J Clin Oncol 34 (1), 91-101, 2016
Vascular endothelial growth factor is elevated in ocular fluids of eyes harbouring uveal melanoma: identification of a potential therapeutic window
SR Boyd, D Tan, C Bunce, A Gittos, MH Neale, JL Hungerford, ...
British Journal of Ophthalmology 86 (4), 448-452, 2002
Phase Ib/II study of capmatinib (INC280) plus gefitinib after failure of epidermal growth factor receptor (EGFR) inhibitor therapy in patients with EGFR-mutated, MET factor†…
YL Wu, L Zhang, DW Kim, X Liu, DH Lee, JCH Yang, MJ Ahn, ...
Journal of Clinical Oncology 36 (31), 3101-+, 2018
The system can't perform the operation now. Try again later.
Articles 1–20